Acceptability of cannabidiol as a treatment for people at clinical high risk for psychosis
Abstract Background: At present, there are no approved pharmacological treatments for people at clinical high risk for psychosis (CHR-P). We…
Paolo Fusar-Poli
PSYSCAN multi-centre study: baseline characteristics and clinical outcomes of the clinical high risk for psychosis sample
Abstract Predicting outcomes in individuals at clinical high risk (CHR) of developing psychosis remains challenging using clinical metrics alone. The…
Balancing risks and benefits of cannabis use: umbrella review of meta-analyses of randomised controlled trials and observational studies
Abstract Objective: To systematically assess credibility and certainty of associations between cannabis, cannabinoids, and cannabis based medicines and human health,…
Does cannabidiol make cannabis safer? A randomised, double-blind, cross-over trial of cannabis with four different CBD:THC ratios
Abstract As countries adopt more permissive cannabis policies, it is increasingly important to identify strategies that can reduce the harmful…
Structural and Functional Imaging Studies in Chronic Cannabis Users: A Systematic Review of Adolescent and Adult Findings
Abstract Background: The growing concern about cannabis use, the most commonly used illicit drug worldwide, has led to a significant…